Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

This study provides Class II evidence that satralizumab reduces the risk of relapse in patients with AQP4-IgG+ NMOSD beyond the first 96 weeks of treatment.

Source: Neurology Neuroimmunology and Neuroinflammation - December 8, 2022 Category: Neurology Authors: Kleiter, I., Traboulsee, A., Palace, J., Yamamura, T., Fujihara, K., Saiz, A., Javed, A., Mayes, D., Büdingen, H.-C. v., Klingelschmitt, G., Stokmaier, D., Bennett, J. L. Tags: Research Article Source Type: research